Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
We support the design and optimization of CAR candidates for targeted in vivo CAR-T development, covering target assessment, binder selection, CAR architecture, payload engineering, and candidate screening. Our approach integrates antigen characteristics, CAR signaling requirements, expression strategy, and targeted LVV compatibility to identify candidates suitable for downstream in vitro validation and in vivo evaluation.
In vivo CAR-T development requires CAR design to be considered together with delivery and expression requirements. Our designs are therefore developed with downstream targeted LVV engineering and functional validation in mind.
Our service follows an integrated four-stage workflow:
Target & Binder Selection
CAR Architecture Design
Payload Engineering
Candidate Screening & Lead Selection
Target Assessment & Selection
A well-defined target strategy is essential for the design of safe and effective CAR candidates. We assess target characteristics in the context of disease biology, intended cell population, target accessibility, and potential therapeutic window.
Key Assessment Parameters:
Target selection is evaluated holistically. High expression alone may not be sufficient; antigen density, epitope accessibility, normal-tissue distribution, and functional therapeutic window must also be considered.
Binder Selection & Optimization
We support the identification, evaluation, and optimization of antigen-binding domains suitable for the intended CAR format and application.
Supported Binder Formats:
Binder Evaluation Criteria:
Affinity optimization is guided by the biological context. For certain targets, maximizing affinity may increase the risk of non-specific activation or recognition of low-density antigen on normal tissues; therefore, the optimal binder profile is determined on a project-specific basis.
Following target and binder selection, we design and optimize CAR configurations to balance antigen recognition, receptor expression, activation threshold, functional persistence, and signaling control.
CAR Architecture
CAR constructs may incorporate different combinations of the following elements:
Architecture selection is guided by target epitope location, antigen density, molecular geometry, intended activation profile, and downstream development objectives.
Expression and Signaling Optimization
CAR architecture can significantly affect receptor surface expression, activation behavior, and functional profile. We assess and compare construct configurations based on relevant expression and signaling parameters.
Key Evaluation Areas:
Where appropriate, multiple architecture variants may be designed and comparatively evaluated to identify candidates with differentiated signaling or expression characteristics.
In in vivo CAR-T development, CAR design and payload engineering are closely interconnected. The transgene cassette must support the intended biological activity while remaining compatible with vector manufacturing, targeted delivery, and downstream functional evaluation.
Payload Design and Expression Strategy
We design genetic payloads that support CAR expression and, where scientifically justified, incorporate additional functional or regulatory modules.
Payload Design Considerations:
Targeted LVV Compatibility Assessment
Payloads are evaluated with downstream targeted LVV development in mind. This early assessment helps identify design features that could influence vector engineering, transgene expression, or subsequent functional characterization.
Key Considerations
This integrated approach supports the selection of payloads that are both scientifically rational and practical for subsequent vector engineering and preclinical evaluation.
Multiple CAR configurations can be generated and comparatively evaluated to identify candidates that best fit the project objectives.
Comparative Candidate Evaluation
| Evaluation Area | Representative Parameters |
| Target Recognition | Specificity, antigen recognition, target-cell selectivity |
| Binding Properties | Affinity, epitope characteristics, cross-reactivity |
| CAR Expression | Surface expression, expression stability, receptor assembly |
| Signaling Profile | Activation threshold, antigen-dependent signaling, tonic signaling |
| Functional Activity | Cytotoxicity, activation markers, cytokine response |
| Payload Performance | Expression profile, cassette organization, construct complexity |
| Development Feasibility | Construct quality, targeted LVV compatibility, downstream study suitability |
Candidate prioritization is based on an integrated assessment of design, expression, functional, and development parameters, with criteria tailored to project objectives.
Lead Candidate Selection
Based on comparative characterization, we help prioritize CAR candidates for downstream development.
Selected candidates can proceed to:
Targeted LVV Engineering
In Vitro Transduction & Functional Assessment
In Vivo CAR-T Pharmacology & Translational Studie
Depending on project scope and starting materials, deliverables may include:
1Target assessment summary
2Selected or optimized binder candidates
3Binder sequence information, where applicable
4CAR architecture designs
5CAR construct sequences and design maps
6Payload design schemes
7Candidate comparison data
8Lead candidate prioritization report
9Design documentation for downstream targeted LVV engineering
Our CAR discovery and payload design capabilities can support:
Development Applications
Disease Areas
CAR development begins with target expression, antigen density, accessibility, and therapeutic-window considerations.
Binder selection, receptor architecture, signaling, and payload design are evaluated as an interconnected system.
CAR candidates are designed with targeted LVV delivery and in vivo expression requirements in mind.
Comparative evaluation helps identify lead candidates rather than simply generating individual CAR constructs.
Selected CAR candidates can transition directly into Targeted Lentiviral Vector Engineering, followed by in vitro and in vivo validation.
What information is needed to start a CAR discovery project?
Projects can begin with a target of interest, antigen information, customer-provided binder or CAR sequence, or a defined therapeutic concept. The appropriate starting point depends on the development stage and project objectives.
Can you work with customer-provided CAR sequences?
Yes. Customer-provided CAR or binder sequences can be evaluated and optimized according to the project requirements, including architecture, expression, payload configuration, and downstream LVV compatibility.
Can you design dual-target or multi-target CARs?
Yes. Dual-target and multi-target CAR configurations can be considered where appropriate, with design and comparative evaluation tailored to the target biology and intended application.
Can selected CAR candidates be directly advanced to targeted LVV development?
Yes. Selected candidates can be carried forward into targeted LVV engineering, enabling continuity between CAR design, vector development, and downstream functional evaluation.
Copyright © 2026 Creative Biogene. All rights reserved.